Plato Investment Management Ltd Grows Holdings in Eli Lilly and Company $LLY

Plato Investment Management Ltd raised its stake in Eli Lilly and Company (NYSE:LLY) by 6.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 17,492 shares of the company’s stock after purchasing an additional 1,037 shares during the period. Eli Lilly and Company accounts for approximately 1.0% of Plato Investment Management Ltd’s holdings, making the stock its 13th biggest holding. Plato Investment Management Ltd’s holdings in Eli Lilly and Company were worth $13,586,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of LLY. PNC Financial Services Group Inc. increased its position in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the last quarter. Nuveen LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter worth about $4,613,912,000. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Eli Lilly and Company by 106.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after purchasing an additional 765,010 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Eli Lilly and Company by 13.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock worth $4,808,443,000 after purchasing an additional 682,203 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. dropped their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. UBS Group lowered their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. HSBC boosted their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the company an “outperform” rating in a research report on Monday, October 20th. Finally, Leerink Partnrs downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $940.00.

Insider Transactions at Eli Lilly and Company

In other news, CEO David A. Ricks bought 1,632 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director J Erik Fyrwald bought 1,565 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 4,514 shares of company stock worth $2,894,841 in the last quarter. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

NYSE LLY opened at $862.96 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market cap of $816.76 billion, a price-to-earnings ratio of 56.40, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. The company has a 50-day moving average price of $780.74 and a two-hundred day moving average price of $771.71.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.